Literature DB >> 22787503

Recognizing and treating peripartum depression.

Bettina Hübner-Liebermann1, Helmut Hausner, Markus Wittmann.   

Abstract

BACKGROUND: In this article, we review current data on the prevalence of, risk factors for, and treatment of peripartum depression.
METHOD: Pertinent publications were retrieved by searches in Medline and the Cochrane Library using the key words "peri/pre/post", "partum/partal/natal", "maternal/motherhood/pregnancy", and "depression/affective disorder".
RESULTS: Depression is the most common peripartal disease: The prevalence of depressive disorders is 18.4% during pregnancy and 19.2% in the puerperium. Prepartum depression is associated with preterm birth, low birth weight, and an abnormal fetal heart rate. In the long run, children of depressed mothers have been found to have impaired cognitive and emotional abilities. Risk factors for peripartal depression include prior depression, poor social support, poor quality of intimate relationship, and negative live events. Peripartum depression can be treated effectively with psychotherapy or drug therapy. Current data support the use of antidepressants during pregnancy and breastfeeding. In many places, pregnancy counseling centers offer low-threshold psychosocial assistance. Nonetheless, no more than 20% of the affected women are identified, even though rapid screening would be possible with instruments such as the Edinburgh Postnatal Depression Scale (EPDS) and the two Whooley questions.
CONCLUSION: Peripartum depression is both common and treatable. Screening for depression should become a routine part of both prepartum care by gynecologists and postpartum care by midwives. This will only be possible, however, with expanded availability of ambulatory and inpatient psychotherapy and psychiatric care for the affected women and their children.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22787503      PMCID: PMC3394379          DOI: 10.3238/arztebl.2012.0419

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   5.594


  47 in total

1.  The treatment of women with epilepsy.

Authors:  Sabine Weil; Charlotte Deppe; Soheyl Noachtar
Journal:  Dtsch Arztebl Int       Date:  2010-11-12       Impact factor: 5.594

2.  Psychosocial risk factors to major depression after childbirth.

Authors:  Philip Boyce; Anthea Hickey
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2005-08-17       Impact factor: 4.328

Review 3.  Impact of antenatal and postpartum maternal mental illness: how are the children?

Authors:  Sarah R Brand; Patricia A Brennan
Journal:  Clin Obstet Gynecol       Date:  2009-09       Impact factor: 2.190

4.  Efficacy of interpersonal psychotherapy for postpartum depression.

Authors:  M W O'Hara; S Stuart; L L Gorman; A Wenzel
Journal:  Arch Gen Psychiatry       Date:  2000-11

Review 5.  Psychosocial and psychological interventions for preventing postpartum depression.

Authors:  C L Dennis; D Creedy
Journal:  Cochrane Database Syst Rev       Date:  2004-10-18

Review 6.  Interventions (other than pharmacological, psychosocial or psychological) for treating antenatal depression.

Authors:  Cindy-Lee Dennis; Kim Allen
Journal:  Cochrane Database Syst Rev       Date:  2008-10-08

7.  [Interactional therapy program for mothers with postpartum mental disorders. First results of a pilot project].

Authors:  C Hornstein; P Trautmann-Villalba; E Hohm; E Rave; S Wortmann-Fleischer; M Schwarz
Journal:  Nervenarzt       Date:  2007-06       Impact factor: 1.214

8.  Association between diabetes and perinatal depression among low-income mothers.

Authors:  Katy Backes Kozhimannil; Mark A Pereira; Bernard L Harlow
Journal:  JAMA       Date:  2009-02-25       Impact factor: 56.272

Review 9.  Psychosocial and psychological interventions for treating antenatal depression.

Authors:  C-L Dennis; L E Ross; S Grigoriadis
Journal:  Cochrane Database Syst Rev       Date:  2007-07-18

Review 10.  Depression during pregnancy: rates, risks and consequences--Motherisk Update 2008.

Authors:  Sheila M Marcus
Journal:  Can J Clin Pharmacol       Date:  2009-01-22
View more
  26 in total

1.  Altered stress patterns and increased risk for postpartum depression among low-income pregnant women.

Authors:  Kathryn Scheyer; Guido G Urizar
Journal:  Arch Womens Ment Health       Date:  2015-08-15       Impact factor: 3.633

2.  A randomized, placebo-controlled, double-blind trial of sertraline for postpartum depression.

Authors:  Liisa Hantsoo; Deborah Ward-O'Brien; Kathryn A Czarkowski; Ralitza Gueorguieva; Lawrence H Price; C Neill Epperson
Journal:  Psychopharmacology (Berl)       Date:  2013-10-31       Impact factor: 4.530

3.  Predictors of psychological distress in low-income mothers over the first postpartum year.

Authors:  Harry Adynski; Catherine Zimmer; John Thorp; Hudson P Santos
Journal:  Res Nurs Health       Date:  2019-03-19       Impact factor: 2.228

4.  Evidence needs to be presented.

Authors:  David Zilles
Journal:  Dtsch Arztebl Int       Date:  2013-01-07       Impact factor: 5.594

5.  Metabolic derailment should be considered.

Authors:  A M Das
Journal:  Dtsch Arztebl Int       Date:  2013-01-07       Impact factor: 5.594

6.  Oxytocin concentrations are crucial.

Authors:  Gudrun von der Ohe
Journal:  Dtsch Arztebl Int       Date:  2013-01-07       Impact factor: 5.594

7.  In reply: Successful bonding is important.

Authors:  Markus Wittmann
Journal:  Dtsch Arztebl Int       Date:  2013-01-07       Impact factor: 5.594

8.  Somatic causes were omitted.

Authors:  Joachim Feldkamp; Matthias Schott
Journal:  Dtsch Arztebl Int       Date:  2013-01-07       Impact factor: 5.594

9.  Successful bonding is important.

Authors:  Gisela Meese
Journal:  Dtsch Arztebl Int       Date:  2013-01-07       Impact factor: 5.594

10.  Digilego for Peripartum Depression: A Novel Patient-Facing Digital Health Instantiation.

Authors:  Alexandra Zingg; Deevakar Rogith; Jerrie S Refuerzo; Sahiti Myneni
Journal:  AMIA Annu Symp Proc       Date:  2021-01-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.